According to Zacks, “Envista Holdings Corporation manufactures and sells dental products primarily in the United States and internationally. The company’s Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics and dental eye loupes to oral surgeons, prosthodontists and periodontists; Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products. Envista Holdings Corporation is based in Brea, California. “
Separately, Evercore ISI started coverage on shares of Envista in a research report on Tuesday, December 17th. They set an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. Envista currently has an average rating of “Buy” and a consensus price target of $32.56.
Envista (NASDAQ:NVST) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.03. The company had revenue of $720.50 million for the quarter, compared to analyst estimates of $729.38 million. During the same period in the previous year, the business posted $0.59 EPS. The firm’s quarterly revenue was down 5.1% compared to the same quarter last year.
A number of hedge funds have recently bought and sold shares of NVST. Oppenheimer Asset Management Inc. bought a new stake in Envista in the third quarter valued at $218,000. Eos Focused Equity Management L.P. acquired a new position in shares of Envista during the third quarter valued at $1,723,000. SG Americas Securities LLC acquired a new position in shares of Envista during the third quarter valued at $173,000. Tower Research Capital LLC TRC acquired a new position in shares of Envista during the third quarter valued at $46,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of Envista during the third quarter valued at $55,215,000.
Envista Holdings Corporation manufactures and sells dental products in the United States and internationally. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Ormco, Insignia, AOA, and Spark brands.
Featured Article: Learning About the VIX – Volatility Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.